Zymergen

Zymergen

Zymergen, founded in 2013 and located in Emeryville, California, is a technology company providing organisms engineering services. Their biotechnology labs rely on advanced manufacturing technologies, machine learning techniques, and genomics to accelerate the design, build, test cycle of microorganisms.

Zymergen, founded in 2013 and located in Emeryville, California, is a technology company providing organisms engineering services. Their biotechnology labs rely on advanced manufacturing technologies, machine learning techniques, and genomics to accelerate the design, build, test cycle of microorganisms. Zymergen claims they have the world's largest database of proprietary physical and digital DNA library in the world. The company provides their services to industrial biotechnology customers seeking to improve the cost efficiency of existing strains, or engineer new strains, that manufacture chemicals, food or food additives, and materials using microorganisms.

Partnership, mergers and acquisitions
Radiant Genomics

On January 8, 2018 Zymergen acquired a functional metagenomics research company named Radiant Genomics. With this acquisition Zymergens gets to add the metagenomic technologies and genetic libraries developed by Radiant Genomics to its core platform. Zymergen hopes acquiring Radiant Genomics will help accelerate its ability to identify and create useful organisms and molecules. The CEO of Zymergen had the following to say about the acquisition: "Radiant has built an unparalleled platform and set of libraries to search genetic diversity that will allow us to search for these molecules of interest, extending our ability to produce useful molecules for materials that can transform the world around us."

Funding
Seed round

On January 1, 2014 Zymergen raised $2,000,000 in seed funding from Genoa Ventures (lead investor), Linden Mobile Ventures, Josh Perfetto, Jesse Robbins, Jenny Rooke, and David Beyer.

Series A

On June 16, 2015 Zymergen completed their Series A funding round raising $42,000,000 in funding from Data Collective (lead investor), AME Cloud Ventures, DFJ, Genoa Ventures, Two Sigma Ventures, True Ventures, SciFI VC, Obvious Ventures, Innovation Endeavors, and Jenny Rooke.

Series B

On October 11, 2016 Zymergen completed their Series B funding round raising $130,000,000 in funding from Soft Bank (lead investor), Two Sigma, Tao Capital Partners, Prelude Ventures, Obvious Ventures, Innovation Endeavors, ICONIQ Capital, Data Collective, DFJ, and AME Cloud Ventures.

Timeline

September 2020
Zymergen raises a $300,000,000 series D round from Baron Capital Group, Baillie Gifford and Perceptive Advisors.
December 2018
Zymergen raises a $400,000,000 series C round from Goldman Sachs, Innovation Endeavors, DFJ, True, DCVC Bio, Two Sigma Ventures, SoftBank Group and Hanwha Asset Management.
January 8, 2018
Zymergen acquires Radiant Genomics

On January 8, 2018 Zymergen acquired a functional metagenomics research company named Radiant Genomics. With this acquisition Zymergens gets to add the metagenomic technologies and genetic libraries developed by Radiant Genomics to it's core platform. Zymergen hopes acquiring Radiant Genomics will help accelerate it's ability to identify and create useful organisms and molecules. The CEO of Zymergen had the following to say about the acquisition of radiant genomics "Radiant has built an unparalleled platform and set of libraries to search genetic diversity that will allow us to search for these molecules of interest, extending our ability to produce useful molecules for materials that can transform the world around us."

October 11, 2016
Zymergen completes $130 million dollar Series B funding round.

On October 11, 2016 Zymergen completed their Series B funding round raising $130,000,000 in funding from Soft Bank (lead investor), Two Sigma, Tao Capital Partners, Prelude Ventures, Obvious Ventures, Innovation Endeavors, ICONIQ Capital, Data Collective, DFJ, and AME Cloud Ventures.

October 11, 2016
Zymergen raises a $130,000,000 series B round from Softbank, Innovation Ventures, Tao Capital Partners, AME Cloud Ventures, Obvious Ventures, ICONIQ Capital, Two Sigma Ventures, Threshold Ventures, Data Collective and Prelude Ventures.
July 16, 2015
Zymergen completes $42 million dollar Series A funding round.

On June 16, 2015 Zymergen completed their Series A funding round raising $42,000,000 in funding from Data Collective (lead investor), AME Cloud Ventures, DFJ, Genoa Ventures, Two Sigma Ventures, True Ventures, SciFI VC, Obvious Ventures, Innovation Endeavors, and Jenny Rooke.

June 16, 2015
Zymergen raises a $42,100,000 series A round from Genoa Ventures, Innovation Endeavors, SciFi VC, AME Cloud Ventures, Obvious Ventures, Two Sigma Ventures, True Ventures, Data Collective and Threshold Ventures.
January 1, 2014
Zymergen completes $2 million dollar seed funding round.

On January 1, 2014 Zymergen raised $2,000,000 in seed funding from Genoa Ventures (lead investor), Linden Mobile Ventures, Josh Perfetto, Jesse Robbins, Jenny Rooke, and David Beyer.

January 1, 2014
Zymergen raises a $2,000,000 seed round from Genoa Ventures, Josh Perfetto, David Beyer, Linden Mobile Ventures and Jenny Rooke.
January 1, 2013
Founding of Zymergen

Zymergen, founded in 2013 and located in Emeryville, California, is a technology company providing organisms engineering services.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Zymergen Series B round, October 11, 2016
130,000,000
October 11, 2016
5 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Aaron Kimball

Employee

Andy Warner

Investor

AngelList Enterprise Fund Manager

Investor

Anna Osterlind

Employee

Ashleigh Korwatch

Employee

Brad Gallagher

Employee

Brock Siegel

Investor

Cok Mudde

Investor

David Beyer

Investor

David McClary

Investor

David St Clair

Advisor

Dmitriy Ryaboy

Employee

Douglas Onsi

Investor

Eric Anschutz

Investor

Euan Guttridge

Investor

Farzad Brian Samimi

Investor

Frazana Sattar

Employee

Jed Dean

VP of Operations and Engineering, Co-founder

Jeff Huber

Investor

Jenny Rooke

Investor

Jerel Davis

Investor

Jeremy LaTrasse

Investor

Jesse Robbins

Investor

John Eaton

Investor

John Levisay

Investor

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Bay-Area biotech startup Zymergen opens Seattle office, signaling big growth plans in the city

Clare McGrane

News article

SoftBank Wants to Build the Future. Here Are Some New Bets It Could Make.

Michael J. de la Merced

News article

What You Need to Know About Zymergen | BioSpace

Mark Terry

Web article

Zymergen Acquires Metagenomics Company Radiant Genomics

Business Wire

News article

Documentaries, videos and podcasts

Title
Date
Link

Designing a Million Genomes: Machine Learning, Automation and Biotech

October 7, 2015

Joshua Hoffman - CEO, Zymergen | Near Future Summit

November 15, 2016

KPMGVoice: Zymergen - The Great Rewrite | Forbes

May 4, 2017

Zymergen: Unlocking the Power of Biology through Technology - Zach Serber at impact.tech at GoogleSF

August 13, 2016

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Megan Hernbroth
January 27, 2021
Business Insider
Since Vision Fund I launched in 2017, the Japanese behemoth has backed 11 US healthcare startups, with a focus on biotechnology companies.
Jonathan Shieber
August 26, 2020
TechCrunch
There's a growing wave of commercial activity from companies that are creating products using new biological engineering technologies. Perhaps the most public (and tastiest) example of the promise biomanufacturing holds is Impossible Foods . The meat replacement company whose ground plants (and bioengineered additives) taste like ground beef just raised another $200 million earlier this [...]
Lizette Chapman
Invalid Date
DealStreetAsia
New backers in the round include Goldman Sachs Group Inc. and Hanwha Asset Management.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.